secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-303796
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion presents preclinical data for BMF-500 at ASH; IND on track for H1 2023
--------------------------------------------------------------------------------

- BMF-500 demonstrated picomolar affinity to FLT3 mutations, including ITD and TKD.
- Complete tumor regression in FLT3-ITD xenograft models; effect maintained without continuous exposure.
- Three-hour pulse of BMF-500 outperformed continuous gilteritinib exposure in cell killing.
- IND submission for BMF-500 planned for first half of 2023.
- BMF-500 showed high selectivity with minimal off-target cytotoxicity across 20 cancer cell lines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522303796/0001193125-22-303796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522303796/d424536d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer